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More people receive tamoxifen for cancer than any other drug 
or therapy (1). Tamoxifen improves disease-free and overall 
survival as an adjuvant treatment for pre- and postmenopausal 
patients with hormone receptor–positive breast cancer (2), in-
duces prolonged responses in patients with hormonally respon-
sive metastatic disease, and substantially reduces the incidence of 
breast cancer in women at increased risk for the disease (3). 
However, thromboembolic events (TEs) are among the most 
serious complications associated with tamoxifen use. In a meta-
analysis of four primary prevention trials that compared tamoxifen 
vs a placebo, tamoxifen use was estimated to increase overall TE 
risk in healthy women by about twofold (relative risk = 1.9, 95% 
confidence interval [CI] = 1.4 to 2.6) and to be associated with 
even higher risks in women aged 50 years or older (4). In the 
National Surgical Adjuvant Breast and Bowel Project (NSABP) 
B-14 trial, in which 5 years of adjuvant tamoxifen use was com-
pared with use of a placebo in women with estrogen receptor– 
positive lymph node–negative breast cancer, the incidence of TE 
was fourfold greater overall in the tamoxifen-treated group 
(1.7%) than in the group receiving placebo (0.4%), with the 
majority of events in women aged 50 years and older (5). The 
prothrombotic effect of 6 months of adjuvant chemotherapy 
plus tamoxifen was assessed in the NSABP B-20 trial, in which 
women who received adjuvant chemotherapy plus tamoxifen had 
approximately threefold more TE (6.5%–7.0%) than women 
who took tamoxifen alone (1.8%). The increased risk was limited 
to the treatment period (6,7). Although the thrombogenic effect 
of tamoxifen is well documented, the effect of underlying breast 
cancer is less well quantified. In the B-14 trial, women with 
breast cancer in the placebo group had a higher rate of breast 
cancer recurrence than did women in the tamoxifen-treated 
group. However, the cumulative TE rate in the placebo group 
was about 0.4% over 5 years, the same rate as among women 
who took a placebo in the NSABP P-1 Breast Cancer Prevention 
Trial, in which participants had elevated breast cancer risk but 
no breast cancer history.
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 Background Tamoxifen use has been associated with increased risk of thromboembolic events (TEs) in women with breast 
cancer and women at high risk for the disease. Factor V Leiden (FVL) is the most common inherited clotting 
factor mutation and also confers increased thrombosis risk. We investigated whether FVL was associated with 
TE risk in women with early-stage breast cancer who took adjuvant tamoxifen.
 Methods A case–control study was conducted among 34 Cancer and Leukemia Group B (CALGB) institutions. We 
matched each of 124 women who had experienced a documented TE while taking adjuvant tamoxifen for breast 
cancer (but who were not necessarily on a CALGB treatment trial) to two control subjects (women who took 
adjuvant tamoxifen but did not experience TE) by age at diagnosis (±5 years). DNA from blood was analyzed for 
FVL mutations. Conditional logistic regression was used to estimate odds ratios (ORs) and to evaluate other 
potential factors associated with TE and tamoxifen use. All P values are based on two-sided tests.
 Results FVL mutations were identified in 23 (18.5%) case and 12 (4.8%) control subjects (OR = 4.66, 95% confidence 
interval = 2.14 to 10.14, P < .001). In the multivariable model, FVL mutation was associated with TE (OR = 4.73, 
95% confidence interval = 2.10 to 10.68, P < .001). Other statistically significant factors associated with TE risk 
were personal history of TE and smoking.
 Conclusions Among women taking adjuvant tamoxifen for early-stage breast cancer, those who had a TE were nearly five 
times more likely to carry a FVL mutation than those who did not have a TE. Postmenopausal women should 
be evaluated for the FVL mutation before prescription of adjuvant tamoxifen if a positive test would alter 
therapeutic decision making.
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It is important to determine the baseline risk for development 
of TE to assess the risk–benefit profile of tamoxifen for a given 
patient. Patients with breast cancer may be at increased risk for 
TE because of their malignancy, surgery, central vascular access 
devices, chemotherapy, and/or inherited or acquired hypercoagu-
lable states. The most common cause of an inherited hypercoagu-
lable state is the factor V Leiden (FVL) mutation, a single G → A 
transition at position 1691 of the gene for factor V (8). The FVL 
mutation results in a loss of one of the three activated protein C 
cleavage sites in factor V, which renders the protein resistant to the 
anticoagulant activity of activated protein C (9). The FVL mutation 
is a dominant trait, with a 2%–5% incidence in the non-Hispanic 
white population and lower prevalence in other ethnic groups 
(10,11).
Presence of the FVL mutation is associated with an increased 
risk of thrombosis in patients with other extrinsic risk factors for 
TE, including hormone replacement therapy (HRT), high-dose 
oral contraceptives, and pregnancy (12–14). We hypothesized 
that a similar association might exist between FVL and tamoxifen-
associated TE because the estrogen agonist activity of tamoxifen is 
thought to confer additional risk of TE. In addition, a 1997 case 
report described three patients (two on adjuvant treatment for 
breast cancer and one with metastatic melanoma) who developed 
TE while on tamoxifen and were found to have the FVL mutation 
(15). This finding suggested to us that a pharmacogenetic study 
might help to determine the relationship between the FVL muta-
tion and TE risk to patients taking tamoxifen. Therefore, we 
designed a case–control study under the auspices of the Cancer and 
Leukemia Group B (CALGB). Our goals were 1) to estimate the 
prevalence of the FVL mutation among patients with early-stage 
breast cancer who had experienced thrombosis while taking adju-
vant tamoxifen, 2) to compare the frequency of the FVL mutation 
among patients who took adjuvant tamoxifen and experienced 
thrombosis with that among age-matched patients who took 
tamoxifen without thrombosis, and 3) to evaluate other factors that 
might contribute to the occurrence of TE during use of adjuvant 
tamoxifen for early-stage breast cancer.
Subjects and Methods
Subjects
The study population consisted of 412 women who received 
tamoxifen as adjuvant treatment for stage I, II, or IIIA breast can-
cer at one of the 34 CALGB main member or Community Clinical 
Oncology Program institutions. This study was approved by the 
Executive Committee of the CALGB; participating institutions 
and practices obtained protocol approval from their local 
Institutional Review Boards. Eligible women, who were aged 
80 years or younger and had received adjuvant tamoxifen either as 
the sole adjuvant systemic therapy or concurrent with or following 
adjuvant chemotherapy, were enrolled between January 15, 1999, 
and April 1, 2005. Patients were accrued by physicians affiliated 
with CALGB; however, patients were not required to have been 
on a CALGB treatment trial. Patients were registered by the 
CALGB Statistical Center.
Case patients were women who developed a venous or arterial 
embolism or deep venous thrombosis while taking adjuvant tamox-
cONteXt AND cAVeAtS
Prior knowledge
Although both use of tamoxifen and factor V Leiden (FVL) mutation 
are independent risk factors for thromboembolic events  (TEs), it was 
not known whether women who take adjuvant tamoxifen for breast 
cancer are at increased risk of TE if they have the FVL mutation.
Study design
A case–control study was designed to match 124 women who took 
tamoxifen for breast cancer and developed TE to 248 women who 
took tamoxifen but did not develop TE. All women were tested for 
the FVL mutation.
Contribution
FVL mutations were found in 23 (18.5%) case subjects vs 12 (4.8%) 
control subjects so in this setting, FVL mutations are associated 
with greater risk of TE.
Implications
Clinicians should consider testing breast cancer patients for FVL 
mutations before prescribing adjuvant tamoxifen if it would alter 
management.
Limitations
Family histories of TE were not confirmed, data were not available 
for every parameter that might confer risk of TE, and tamoxifen in 
combination with anticoagulants was not studied.
From the Editors
 
ifen for stage I, II or IIIA breast cancer. Superficial phlebitis was 
not considered a thrombotic event. Catheter-associated thrombo-
sis sufficient to require removal of the catheter was considered a 
TE for the purpose of case eligibility, but catheter-associated clots 
that resolved with thrombolytic therapy alone were not sufficient 
for case status. Use of heparin or warfarin during adjuvant therapy 
before the TE rendered potential subjects ineligible. Medical 
record documentation of the reported thromboembolic event 
and its therapy were provided for central review in 96% of case 
subjects.
Control subjects were women who did not develop a venous or 
arterial embolism while taking tamoxifen as adjuvant treatment for 
stage I, II, or IIIA breast cancer at a CALGB institution, though 
not necessarily on a CALGB treatment trial. Women who used 
heparin or warfarin during adjuvant therapy were ineligible. 
Patients who experienced a thrombotic or embolic event more 
than 2 months after completion of adjuvant tamoxifen therapy 
were eligible to participate as control subjects, although none was 
enrolled. Two control subjects were matched to each case patient 
by age at breast cancer diagnosis (±5 years) and enrolling institu-
tion but not by treatment with adjuvant chemotherapy. Enrollment 
of the triplet (one case subject plus two control subjects from the 
case institution) was successful for 85% of case subjects; the final 
control subjects, who were matched to each case subject by age at 
breast cancer diagnosis (±5 years), were enrolled from the institu-
tions that accrued the largest number of case–control triplets 
(Figure 1).
Consenting case and control subjects were interviewed 
regarding the number of their pregnancies, their menopause status 
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(clinical definition, documentation not required), the number of 
months they took postmenopausal HRT before their breast cancer 
diagnosis, their smoking status while on adjuvant therapy, and 
their history of TE (personal and in first-degree relatives). Other 
data were collected from medical records: age at breast cancer 
diagnosis, cancer stage, date of diagnosis, adjuvant chemotherapy 
use, and personal history of prior TE. Reported family histories of 
TE were not validated from medical records.
Determination of FVL Mutation Status
Blood specimens were obtained from eligible women after appro-
priate informed consent. All specimens were centrally processed 
and aliquoted at the DNA Processing Laboratory at the University 
of North Carolina. DNA was extracted from whole blood, and 
polymerase chain reaction to detect the FVL mutation was per-
formed in the research laboratory of N. Berliner at Yale Medical 
School. A 221-base pair fragment that spanned the 3′ end of exon 
10 and the 5′ end of intron 10 of the Factor V gene (GenBank 
accession number: NG_011806; exon 10 nt: 36635–36878) was 
amplified using primers PR-6967 (sense: 5′ TGC CAA GTG 
CTT AAC AAG ACC A 3′ nt: 36611–36632) and PR-990 (anti-
sense 5′ CTT GAA GGA AAT GCC CCA TAA 3′ nt: 36811–
36832). This fragment contains nucleotides 1690–1695, which 
encode the Arg 506-Gly507–activated protein C cleavage site of 
factor V. Amplified DNA fragments were digested with Mnl1 and 
HindIII to find restriction fragment length polymorphisms charac-
teristic of the FVL mutation (G1691A). All reactions were run 
with the appropriate controls including a water-only negative 
control for all polymerase chain reaction reactions and a sample 
bearing a known FLV mutation as a positive control for the 
restriction enzyme digests. The laboratory was not Clinical 
Laboratory Improvement Amendments (CLIA)–certified: per 
protocol, FVL results were not returned to subjects or their treat-
ing physicians. Data were collected and analyzed at the CALGB 
Statistical Center at Duke University.
Statistical Analysis
Assuming a 1:2 case–control ratio, the proportion of discordant 
sets among all sets was 10%, based on the excess risk of TE on 
adjuvant therapy for breast cancer from a large Eastern Cooperative 
Oncology Study (16). A Mantel–Haenszel test required a total of 
120 triplets to achieve a power approximating 80% to detect a 
relative risk of 4 or greater, with a one-sided type I error rate of 
0.05. However, in accordance with the policy of the Journal, only 
two-sided P values are reported. Population attributable risk was 
calculated using a standard formula (17).
Case and control subjects were compared with regard to base-
line characteristics using the x2 statistic for categorical variables 
(race, stage, menopausal status, adjuvant chemotherapy, clotting 
episode, family history of thromboembolism, and smoking history) 
and the Wilcoxon test for continuous variables (age, HRT use, and 
number of pregnancies). Conditional logistic regression analysis 
was performed to estimate the odds ratio (OR) and the 95% con-
fidence interval for the relationship between FVL mutation and 
thromboembolism. Analyses of prior history of clot, family history 
of TE, and smoking history are based on bivariate analysis. These 
parameters were also included in the final multivariable logistic 
regression model to evaluate potential predictors of TE risk in 
women who took adjuvant tamoxifen. All P values were based on 
two-sided tests.
results
Participant, tumor, and treatment characteristics were distributed 
similarly among case and control subjects except for past hormone 
use, blood clot history, and stage, with more women diagnosed at 
stage I among case subjects (Table 1). The study included 412 
women who took adjuvant tamoxifen for breast cancer: 141 case 
and 271 control subjects. The analysis is based on 124 triplets 
matched by age at breast cancer diagnosis (±5 years) because 19 
patients were excluded for lack of matching and 21 patients were 
either ineligible or had incomplete laboratory data (Figure 1). 
Most women were postmenopausal, with a median age of 64 years 
among both case and control subjects. Almost all patients had 
early-stage breast cancer: 91% of case and 95% of control subjects 
had confirmed stage I or II disease. Among the case subjects, 
96 women had deep vein thrombosis, 12 had a pulmonary throm-
boembolism, 12 had both deep vein thrombosis and pulmonary 
thromboembolism, three had an arterial clot, and one patient had 
an intravenous line–related thrombus. Subjects in the control 
group had received postmenopausal HRT for a statistically signif-
icantly longer period of time before breast cancer diagnosis than 
Figure 1. CONSORT diagram of all patients enrolled on CALGB 9872.
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case subjects (median 4 vs 0 months, P = .014). Also, a statistically 
significantly greater proportion of case subjects reported having 
smoked while on tamoxifen therapy compared with control sub-
jects (15% vs 6%, P = .019). Proportionally more case than control 
subjects had experienced a prior episode of TE (14% vs 5%, P = 
.002). Although there were more case than control subjects with a 
family history of TE (20% vs 12%, P = .055), this difference was 
not statistically significant.
A statistically significantly greater proportion of case subjects 
had FVL mutations compared with control subjects (18.5% vs 
4.8%, all heterozygotes; unadjusted OR = 4.66, 95% CI = 2.14 to 
10.14, P < .001). A statistically significantly higher percentage of 
women with the FVL mutation had a personal history of TE com-
pared with those without, and a family history of clot was more 
frequent among those with the mutation (Table 2).
There was not a statistically significant difference in the median 
time from diagnosis of breast cancer to TE among women with the 
FVL mutation compared with those without (13 vs 12 months, 
P = .830, Table 3). The median time from tamoxifen initiation to 
clot was similar in both groups (9 vs 9 months, P = .517).
In the multivariable logistic regression model, the likelihood of 
having had a TE while taking adjuvant tamoxifen (ie, becoming a 
case subject) was statistically significantly increased among women 
who carried the FVL mutation (OR = 4.73, 95% CI = 2.10 to 
10.68, P < .001; Table 4). Other statistically significant factors for 
risk of TE were a personal history of TE, reported smoking during 
adjuvant therapy, and a family history of TE (Table 4).
The population attributable risk percent of TE among women 
with breast cancer taking adjuvant tamoxifen accounted for by 
FVL mutations was 14%, that is, 14% of TE among women taking 
tamoxifen occurred among women with the FVL mutation.
Discussion
This case–control study found an increased risk of a FVL mutation 
among women taking adjuvant tamoxifen for early-stage breast 
Table 1. Patient and clinical characteristics at study enrollment for the 124 triplets*
Demographics Case subjects (N = 124) Control subjects (N = 248) P†
Median age, y (interquartile range) 64 (55.5–71) 64 (54.5–70) .612‡
Median months HRT (interquartile range) 0 (0–48) 4 (0–120) .014‡
Median number pregnancies (interquartile range) 2 (1–3) 2 (1–3) .317‡
Race, No. (%)
 White 110 (89) 230 (93) .171
 Other 13 (10) 16 (6)
 Missing 1 (1) 2 (1)
Stage, No (%)
 I 62 (50) 96 (39) .041
 II 51 (41) 140 (56)
 IIIA 6 (5) 10 (4)
 Missing 5 (4) 2 (1)
Menopausal status at diagnosis§, No. (%)
 Pre 12 (10) 36 (14) .413
 Peri 7 (5) 12 (5)
 Post 105 (85) 200 (81)
Adjuvant chemotherapy, No. (%)
 Yes 57 (46) 130 (52) .241
 No 67 (54) 118 (48)
Type of clot, No (%)
 DVT 96 (77)  
 PE 12 (10) NA
 DVT and PE 12 (10)  
 Arterial embolism 3 (2)  
 Clotted line 1 (1)  
Clotting episode before tamoxifen treatment, No. (%)
 Yes 17 (14) 12 (5) .002
 No 105 (85) 236 (95)
 Missing 2 (1) 0 (0)
Family history of thromboembolism, No. (%)
 Yes 25 (20) 29 (12) .055
 No 76 (61) 179 (72)
 Missing 23 (19) 40 (16)
Smoked on treatment§, No. (%)
 Yes 19 (15) 16 (6) .019
 No 101 (82) 220 (89)
 Missing 4 (3) 12 (5)
* DVT = deep vein thrombosis; HRT = hormone replacement therapy; NA = not applicable; PE = pulmonary thromboembolism.
† All tests except where otherwise indicated were based on the x2 statistic and were two-sided.
‡ Wilcoxon P values based on two-sided tests.
§ Menopause and smoking status were provided by patient at enrollment.
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cancer who experienced a TE compared with those who did not. 
Risk of TE was also increased among women who had had a pre-
vious TE and those who smoked during breast cancer treatment.
Tamoxifen has been an important and effective agent in the 
treatment of patients with hormone receptor–positive breast can-
cer for more than three decades. Its ability to substantially reduce 
the incidence of new hormone receptor–positive invasive and in 
situ breast cancers has been established for women who are at 
increased risk for breast cancer based on family history and other 
risk factors, including prior breast cancer (3,18–20). The duration 
of benefit for both adjuvant and risk-reducing indications extends 
years beyond the initial use (21).
Despite these advantages, both patients and their physicians 
have become increasingly concerned about using tamoxifen because 
of real and perceived adverse effects over the years of its recom-
mended use (22–25). A simple, inexpensive, and widely available 
assay that would identify the subset of women at higher risk for 
one of the most serious adverse effects of tamoxifen would likely 
be attractive to patients and providers. Because of this prospect, we 
examined the potential association between tamoxifen-associated 
TE and the FVL mutation, using a pharmacogenetic approach to 
toxicity assessment. This study demonstrated that women who 
experienced a TE while taking adjuvant tamoxifen for early-stage 
breast cancer were nearly five times more likely to carry a FVL 
mutation compared with women who took adjuvant tamoxifen but 
did not develop a TE.
In the decade after the thrombotic effects of tamoxifen were 
recognized and quantified (26), the FVL mutation was identified, 
and its epidemiology and implications were defined (8,27). A ger-
mline FVL mutation is associated with an annualized rate of TE 
of approximately 2.8%–7.5%; among individuals without FVL, 
annualized event rates range from 1.1% to 3.1% (28). In particular, 
the FVL mutation confers increased risk of TE, and the risk is 
elevated further with female steroid hormone exposures. The 
increased risk of TE among persons heterozygous for the FVL 
mutation has been observed in the presence of both endogenous 
hormonal states like pregnancy (14) and exogenous agents such 
as oral contraceptives (15-fold in a recent study) (13) or HRT 
Table 2. Frequency of factor V Leiden heterozygotes by case–control, prior clotting, and smoking history*
Patient characteristic Total
Factor V Leiden, No. (%)
OR (95% CI) P†Yes No
Case subjects 124 23 (18.5) 101 (81.5)  
Control subjects 248 12 (4.8) 236 (95.2) 4.66 (2.14 to 10.14) <.001
Total 372 35 (9.4) 337 (90.6)  
Prior history of clot
 Case subjects 17 7 (41.2) 10 (58.8)  <.001
 Control subjects 12 0 (0) 12 (100) 4.38 (1.97 to 9.72)
No prior history of clot
 Case subjects 107 16 (15.0) 91 (85.0)  
 Control subjects 236 12 (5.1) 224 (95.9)  
Family history of clot‡
 Case subjects 25 5 (20.0) 20 (80.0) 5.27 (2.17 to 12.82) <.001
 Control subjects 29 1 (3.5) 28 (96.5)  
No family history of clot
 Case subjects 76 15 (19.7) 61 (80.3)  
 Control subjects 179 11 (6.2) 168 (93.8)  
Smoked‡
 Case subjects 19 3 (15.8) 16 (84.2)  <.001
 Control subjects 16 0 (0) 16 (100) 5.01 (2.21 to 11.35)
Did not smoke
 Case subjects 101 19 (18.8) 82 (81.2)  
 Control subjects 220 10 (4.6) 210 (95.5)  
* CI = confidence interval; OR = odds ratio.
† x2 tests based on conditional logistic regression were two-sided.
‡ Women with missing family history or smoking data were excluded from the bivariate analyses.
Table 3. Time to thromboembolic event (TE) in 124 case patients by factor V Leiden mutation status
Median time to thromboembolic event
Factor V Leiden mutation
P‡Yes* No†
From breast cancer diagnosis to TE, mo (interquartile range) 13 (7–24) (n = 22) 12 (6–28) (n = 94) .830
From tamoxifen initiation to TE, mo (interquartile range) 9 (2–23) (n = 23) 9 (3–22) (n = 101) .517
* There were 22 patients with the factor V Leiden mutation who were evaluated for median time from breast cancer diagnosis to TE and 23 for time from  
tamoxifen initiation to TE.
† There were 94 patients without the factor V Leiden mutation who were evaluated for median time from breast cancer diagnosis to TE and 101 for time from 
tamoxifen initiation to TE.
‡ Wilcoxon P values based on two-sided tests.
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(OR = 6.7 in the Women’s Health Initiative) (12). The risks are 
even greater for persons who are homozygous for the FVL muta-
tion. The prevalence of the FVL mutation among ethnic groups in 
the United States is approximately 5% in non-Hispanic whites, but 
only 2.2% among Hispanics, 1.23% among African Americans, and 
less than 1% among Asian Americans (29). Despite the increased 
risks of TE associated with the FVL mutation and hormonal med-
ications, there are currently no recommendations for screening 
asymptomatic populations to identify individuals for anticoagu-
lation or to preclude the introduction of oral contraceptive or 
hormone replacement therapies (30). The identification of the 
FVL mutation in patients with recent clotting events or with a 
history of TE during pregnancy may result in prolongation of 
anticoagulation therapy or initiation of antithrombotic therapy 
during pregnancy or the postpartum period (31).
The potential interaction between the FVL mutation and 
tamoxifen, a serum estrogen receptor modulator with known 
thrombogenic effects that have been attributed to its estrogen 
agonist activity, has been systematically explored in the large 
tamoxifen risk-reduction trials, which should provide the setting in 
which the effects are easiest to discern. The International Breast 
Cancer Intervention Study (IBIS-1) was a nested case–control 
study that assessed intrinsic and acquired risk factors for TE, in 
which women with elevated breast cancer risk based on family 
history were randomized to 5 years of tamoxifen or placebo use. 
That analysis identified surgery, immobilization, and fracture as 
factors associated with increased risk of TE. Both the FVL muta-
tion and the thrombophilic prothrombin G20210A mutation were 
paradoxically confined to the control group, so no association 
between FVL mutation and tamoxifen was demonstrated (32). 
A nested case–cohort study from the NSABP Breast Cancer 
Prevention Trial (P-1), in which tamoxifen was compared with 
placebo in women whose increased breast cancer risk was based on 
multiple risk factors (33), found no association between either 
FVL or the prothrombin G20210A mutation and risk of TE. A 
substantially higher body mass index was observed in women with 
TE in the trial cohort (33).
What might account for the difference between the nearly five-
fold excess of the FVL mutation among women who experienced 
TE while taking tamoxifen in this study and the lack of a relation-
ship between the FVL mutation, tamoxifen use, and risk of TE in 
the IBIS and NSABP P-1 prevention trials? The obvious differ-
ence in the subject populations—women with early-stage breast 
cancer in this study and women at risk but without breast cancer in 
the risk-reduction trials—suggests that effects of the breast cancer 
are important. The risk of recurrence among women with early-
stage hormone receptor–positive breast cancer is low during adju-
vant hormonal therapy and rises after tamoxifen use is stopped 
(34,35). The TE events in this study typically occurred within the 
first 2 years of tamoxifen therapy when the burden of occult breast 
cancer should be small. In a recent analysis of women aged 50 years 
or older on therapeutic tamoxifen, the overall risk of breast cancer 
recurrence within the first 2.5 years of use was 7.9% (36). Similarly, 
in Trial 1-98, a large randomized controlled trial of adjuvant 
hormonal therapies in postmenopausal women with hormone 
receptor–positive breast cancer (37), the Breast International 
Group investigators cited an 8.1% risk of recurrence in the tamoxifen 
Table 4. Logistic regression modeling the probability of the risk of 
thromboembolism among breast cancer patients taking adjuvant 
tamoxifen*
Variable OR (95% CI) P†
Factor V Leiden mutation
 Yes vs no 4.73 (2.10 to 10.68) <.001
Prior history of clot
 Yes vs no 3.05 (1.18 to 7.87) .021
Family history of clot
 Yes vs no 2.06 (1.04 to 4.11) .040
 Unknown vs no 1.34 (0.67 to 2.66) .411
Smoking status
 Yes vs no 2.97 (1.34 to 6.56) .007
 Unknown vs no 0.37 (0.07 to 1.87) .230
* CI = confidence ratio; OR = odds ratio.
† All P values are based on two-sided tests.
arm by 3 years after random assignment. These data suggest that 
it is unlikely that the occurrence of TE in case subjects in our study 
resulted from occult metastatic disease.
A particularly important difference between the tamoxifen-
treated women in our study and those in the large randomized 
tamoxifen prevention trials is that our cohort did not exclude the 
29 women who had a personal history of prior TE from eligibility 
as case subjects (see Table 1). It was certainly more common to use 
tamoxifen, despite a history of TE, in the treatment of postmeno-
pausal women with hormone receptor–positive breast cancer 
before aromatase inhibitors became an established therapeutic 
alternative. The Food and Drug Administration approved aromatase 
inhibitors for adjuvant use only 9 years ago, in 2001. Previous 
history of a clot was an exclusion criterion for the NSABP P-1 trial 
but was not for other adjuvant trials begun in the early 1990s. 
However, in our study, women with a personal history of TE (29 
total) plus those with a family history of TE (54 total) accounted 
for fewer than half of the FVL mutation carriers who had a TE on 
tamoxifen treatment (five and seven case subjects, respectively, vs 
31 case subjects among 598 with no prior personal or family history 
of a clot; see Table 2). If the 29 women with a personal history of TE 
(who were reported as part of 25 triplets) had been excluded, women 
who experienced a TE would still be more likely to have the FVL 
mutation (based on the analysis of 99 triplets, unadjusted OR = 2.77, 
95% CI = 1.13 to 6.80, P = .026; OR adjusted for family history and 
smoking history = 2.71, 95% CI = 1.08 to 6.81, P = .034).
The prevalence of current smoking among case subjects in our 
study was 15%, very similar to the prevalence of current smokers 
in the IBIS prevention trial (19%–21% in case and control sub-
jects) and the prevalence of ever-smokers in NSABP-P1 (13.2% in 
case and 12.9% in control subjects). Among our control subjects, 
only 6% reported current smoking. Current smoking, but not 
former smoking, has been shown to further increase risk of TE 
among women who carry thrombophilic mutations alone (38) and 
in the setting of hormone exposure (39), which should provide 
another impetus for women to stop smoking if they are expected 
to survive their breast cancers.
The etiology of increased risk of TE among patients with 
cancer is not precisely known, although it is thought that cancer 
generally induces a hypercoagulable state by stimulating circulating 
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endothelial and mononuclear cells to express procoagulant mole-
cules, such as tissue factor (40). The volume of cancer necessary to 
induce a clinically significant effect is unknown. Management of 
cancer patients involves the use of prothrombotic measures, such 
as the placement of central venous catheters and the administra-
tion of chemotherapy, which could potentially have long-lasting 
effects on endothelium or clotting proteins. About half of the 
patients in our study had received adjuvant chemotherapy, which 
is thought to increase the risk of TE by damaging the vascular 
endothelium and decreasing plasma levels of coagulation inhibi-
tors (41). However, we found no statistically significant difference 
in chemotherapy exposure between case and control subjects in 
univariate or multivariable analyses. Thus, the difference in che-
motherapy administration is unlikely to explain the prevalence of 
the FVL mutation among women with a tamoxifen-associated 
blood clot in this study. It is most likely that other differences in 
the study populations account for the disparate observations 
between the women in our cohort and those without a history of 
breast cancer in the primary prevention trials.
There are several limitations to this study. Family history of TE 
was more prevalent among the women with TE in this study but 
was not limited to women with the FVL mutation. We did not 
confirm family history of TE with medical records nor were 
potential subjects evaluated for other underlying hereditary coagu-
lopathies, such as deficiencies of protein C, protein S, or anti-
thrombin III, or presence of the prothrombin G20210A mutation, 
though persons with these conditions are rare. We did not collect 
data on parameters that have been shown to mediate risk of TE in 
other cohorts taking tamoxifen, including body mass index, recent 
surgery, or other immobilization (19,33). Because of increased 
awareness of tamoxifen’s procoagulant properties, women with a 
history of TE would not be likely to receive tamoxifen for adjuvant 
therapy in current practice without prophylactic full anticoagulation.
Our data show that women who experience TE events after 
taking tamoxifen have a 4.66-fold chance of carrying the FVL 
mutation. These data may prove useful to women who must decide 
between tamoxifen and an effective, essentially nonthrombogenic, 
alternative adjuvant therapy for breast cancer, such as aromatase 
inhibitors for postmenopausal women and gonadotropin-releasing 
hormone analogs or oophorectomy for premenopausal women. A 
frail woman, for whom the challenge of a TE would be particularly 
dangerous, can eliminate up to 10% of the risk of TE attributable 
to tamoxifen by testing to exclude the possibility that she is 
carrying an FVL mutation. For the population of women with 
estrogen receptor–positive breast cancers, if adjuvant tamoxifen 
were not given to those with FVL mutations, only 14% of TE 
events would be avoided. However, because ongoing trials in post-
menopausal women with hormone receptor–positive breast cancer 
have shown some therapeutic value from sequential administration 
of tamoxifen and an aromatase inhibitor, the issue may arise more 
often in the future (37).
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